View Exam | PowerPak

1. Which of the following is an advantage of intravenous immunoglobulin therapy compared to subcutaneous administration of immunoglobulin for patients with primary immunodeficiency?

A. Fewer infections per year B. Increased quality of life C. Lower risk for anaphylaxis D. Reduced swelling at injection site

2. Which of the following conditions can be treated with immunoglobulin administered via the subcutaneous route?

A. Idiopathic thrombocytopenia purpura B. Common variable immune deficiency C. Kawasaki syndrome D. Multifocal motor neuropathy

3. Conversion to which of the following products would require a dosage adjustment in a patient who had been receiving intravenous immunoglobulin (IVIG) 10% stabilized with glycine?

A. Conventional subcutaneous immunoglobulin (SCIG) 20% stabilized with proline B. SCIG 10% with recombinant human hyaluronidase C. IVIG 10% stabilized with maltose D. IVIG 6% stabilized with sucrose

4. Which of the following commonly used methods of immunoglobulin administration requires the most injection sites?

A. Intravenous immunoglobulin B. Conventional subcutaneous immunoglobulin C. Intramuscular immunoglobulin D. Subcutaneous immunoglobulin with recombinant human hyaluronidase

5. Which of the following comorbid conditions is a contraindication to a patient receiving immunoglobulin via the subcutaneous route?

A. Migraine headaches B. Congestive heart failure C. Diabetes mellitus D. Idiopathic thrombocytopenia purpura

6. Which of the following patients would not be a candidate for self-administration of rapid-push subcutaneous immunoglobulin?

A. A 50-year-old male with common variable immune deficiency (CVID) and hypertension B. A 60-year-old female with CVID and rheumatoid arthritis that causes significant pain and swelling in the wrists and fingers C. A 30-year-old male with Wiskott–Aldrich syndrome (WAS) and diabetes D. A 25-year-old male with WAS and hyperlipidemia

7. Patients with primary immunodeficiency are most likely to have a severe anaphylactic reaction when treated with which of the following types of therapy?

A. Intravenous immunoglobulin B. Conventional subcutaneous immunoglobulin C. Intramuscular immunoglobulin D. Subcutaneous immunoglobulin with recombinant human hyaluronidase

8. The risk of which of the following reactions is more common with subcutaneous immunoglobulin administration than with intravenous immunoglobulin administration?

A. Anaphylaxis B. Headache C. Swelling at injection site D. Hemolysis

9. Which of the following is a disadvantage of traditional subcutaneous immunoglobulin administration?

A. More systemic adverse effects B. Longer time commitment C. Multiple infusion sites D. Decreased quality of life

10. Which of the following is an advantage of immunoglobulin infusion 10% with recombinant human hyaluronidase?

A. Improved safety profile over subcutaneous immunoglobulin (SCIG) B. Similar peak-to-trough variations compared to SCIG C. Higher peak levels than intravenous immunoglobulin (IVIG) D. Less frequent administration than IVIG

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following is an advantage of intravenous immunoglobulin therapy compared to subcutaneous administration of immunoglobulin for patients with primary immunodeficiency?

2. Which of the following conditions can be treated with immunoglobulin administered via the subcutaneous route?

3. Conversion to which of the following products would require a dosage adjustment in a patient who had been receiving intravenous immunoglobulin (IVIG) 10% stabilized with glycine?

4. Which of the following commonly used methods of immunoglobulin administration requires the most injection sites?

5. Which of the following comorbid conditions is a contraindication to a patient receiving immunoglobulin via the subcutaneous route?

6. Which of the following patients would not be a candidate for self-administration of rapid-push subcutaneous immunoglobulin?

7. Patients with primary immunodeficiency are most likely to have a severe anaphylactic reaction when treated with which of the following types of therapy?

8. The risk of which of the following reactions is more common with subcutaneous immunoglobulin administration than with intravenous immunoglobulin administration?

9. Which of the following is a disadvantage of traditional subcutaneous immunoglobulin administration?

10. Which of the following is an advantage of immunoglobulin infusion 10% with recombinant human hyaluronidase?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following is an advantage of intravenous immunoglobulin therapy compared to subcutaneous administration of immunoglobulin for patients with primary immunodeficiency?

2. Which of the following conditions can be treated with immunoglobulin administered via the subcutaneous route?

3. Conversion to which of the following products would require a dosage adjustment in a patient who had been receiving intravenous immunoglobulin (IVIG) 10% stabilized with glycine?

4. Which of the following commonly used methods of immunoglobulin administration requires the most injection sites?

5. Which of the following comorbid conditions is a contraindication to a patient receiving immunoglobulin via the subcutaneous route?

6. Which of the following patients would not be a candidate for self-administration of rapid-push subcutaneous immunoglobulin?

7. Patients with primary immunodeficiency are most likely to have a severe anaphylactic reaction when treated with which of the following types of therapy?

8. The risk of which of the following reactions is more common with subcutaneous immunoglobulin administration than with intravenous immunoglobulin administration?

9. Which of the following is a disadvantage of traditional subcutaneous immunoglobulin administration?

10. Which of the following is an advantage of immunoglobulin infusion 10% with recombinant human hyaluronidase?

« Return to Activity

Customers who Purchased
this Activity also Purchased